Skip to main content

Table 3 Symptoms in patients on somatostatin analogue treatment for metastatic disease from small-intestinal neuroendocrine tumour. EORTC GI.NET-21, values expressed as mean (standard deviation) Higher scores (1–100) indicate more severe symptoms

From: Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours

 Baseline1-year follow-up
Endocrine symptoms15.6 (17.5)13.0 (15.7)
Gastrointestinal symptoms21.2 (15.6)18.7 (15.5)
Treatment-related symptoms12.0 (14.1)10.2 (12.1)
Social functioning27.8 (19.5)25.4 (17.7)
Disease-related worries34.2 (21.5)30.1 (21.9)
Muscle/bone pain31.4 (32.9)25.5 (29.1)
Sexual functioning29.2 (36.4)28.6 (37.8)
Information/communication6.1 (18.6)5.6 (14.7)
Body image16.7 (28.6)13.9 (24.4)